Alliance for Pandemic Preparedness

April 20, 2021

Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York

Category:

Topic:

Keywords (Tags):

  • No difference in ventilator-free days through 28 days (p=0.86) was observed between patients randomized to receive convalescent plasma (CP) vs standard plasma in a 4:1 randomized doubled-blind placebo-controlled trial (n=74). CP increased antibody levels by 14%, whereas standard plasma led to a 7% decrease. All-cause mortality through 90 days was non-significantly lower in the CP group (27% vs 33%, p=0.63). The trial was halted after the FDA granted emergency use authorization for CP.

Bennett-Guerrero et al. (Apr 16, 2021). Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York. Critical Care Medicine. https://doi.org/10.1097/CCM.0000000000005066